|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Structure and function of the blood–brain barrier显示文摘 | N. Joan Abbott Adjanie A.K. Patabendige Diana E.M. Dolman Siti R. Yusof David J. Begley | 2009 | Neurobiology of Disease2009，，1： | 2 |
| 2 | Structure and function of the blood–brain barrier显示文摘 | N. Joan Abbott Adjanie A.K. Patabendige Diana E.M. Dolman Siti R. Yusof David J. Begley | 2009 | Neurobiology of Disease2009，，1： | 1 |
| 3 | Structure and function of the blood–brain barrier显示文摘 | N. Joan Abbott Adjanie A.K. Patabendige Diana E.M. Dolman Siti R. Yusof David J. Begley | 2009 | Neurobiology of Disease2009，，1： | 1 |
| 4 | Structure and function of the blood–brain barrier显示文摘 | N. Joan Abbott Adjanie A.K. Patabendige Diana E.M. Dolman Siti R. Yusof David J. Begley | 2009 | Neurobiology of Disease2009，，1： | 1 |
| 5 | Astrocytic aquaporin 4 subcellular translocation as a therapeutic target for cytotoxic edema in ischemic stroke显示文摘Brain edema is a common feature of several brain diseases(e.g.,stroke,traumatic brain injury,hydrocephalus,brain cancer,and brain infections).Brain edema leads to increased intracranial pressure and worsens outcomes in ischemic stroke patients.Conventional treatments to control brain edema,thus reducing intracranial pressure include different osmotherapeutics,hyperventilation,tromethamine,hypothermia,and barbiturate coma.However,level 1 evidence of efficacy is lacking for these treatments,with some being harmful rather than beneficial(Bardutzky and Schwab,2007).It has been proposed aquaporin 4(AQP4)can be a novel drug target for treating brain edema(Vandebroek and Yasui,2020). | Adjanie Patabendige Ruoli Chen | 2022 | Neural Regeneration Research2022，17，12： | 1 |
| 6 | Efficacy and safety of thermobalancing therapy with Dr Allen’s Device for chronic low back pain:A randomised controlled trial显示文摘BACKGROUND Lumbar disc herniation and non-specific low back pain are common conditions that seriously affect patients’health-related quality of life(HRQoL).Although empirical evidence has demonstrated that novel Thermobalancing therapy and Dr Allen’s Device can relieve chronic low back pain,there have been no randomised controlled trials for these indications.AIM To evaluate the efficacy of Dr Allen’s Device in lumbar disc herniation(LDH)and non-specific low back pain(NSLBP).METHODS A randomised clinical trial was conducted investigating 55 patients with chronic low back pain due to LDH(n=28)or NSLBP(n=27),out of which 15 were randomly assigned to the control group and 40 were assigned to the treatment group.The intervention was treatment with Dr Allen’s Device for 3 mo.Changes in HRQoL were assessed using the Numerical Pain Rating Scale and the Japanese Orthopedic Association Back Pain Questionnaire.RESULTS Thermobalancing therapy with Dr Allen’s Device showed a significant reduction in pain in the treatment group(P<0.001),with no recorded adverse effects.Both pain assessment scales showed a significant improvement in patients’perception of pain indicating improvement in HRQoL.CONCLUSION The out-of-hospital use of Thermobalancing therapy with Dr Allen’s Device for Low Back Treatment relieves chronic low back pain significantly and without adverse effects,improves the level of activity and HRQoL among patients with LDH and NSLBP.This study demonstrates the importance of this safe first-line therapy that can be used for effective at-home management of chronic low back pain. | Simon Allen Abid Rashid Ariana Adjani Muhammad Akram Fahad Said Khan Rehan Sherwani Muhammad Talha Khalil | 2023 | World Journal of Orthopedics2023，14，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员